Indegene

    INDGN
    Pharma
    ₹654.95
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹15,773 Cr

    P/E
    38.53
    Day range
    ₹646.05 – ₹662.55
    52-week range
    ₹414.00 – ₹677.00
    Volume
    3.13 L
    Open
    ₹647.85
    Prev close
    ₹648.75

    Latest results · Q2 FY27(consolidated)Revenue ₹1,122 Cr+39.6%Profit ₹112 Cr+10.0%Margin 10.0%YoY vs the same quarter last year

    1 red flag to read up on

    • medium

      Material exchange filing

      Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer · 29 Oct 2026

    From NSE and BSE filings. A flag is a reason to read the filing, not a rating.

    Research profile

    Composite 66 / 100

    Factor percentiles

    Value54
    Quality49
    Momentum84
    Low volatility77

    Derived metrics

    Earn. yield
    2.6%
    Graham no.
    ₹233.40
    vs Graham
    -64.4%
    ROE ÷ P/B
    2.9%
    12-1 mom.
    +15.4%
    Return / vol
    0.93
    Magic Formula
    #304
    Piotroski
    1/6
    FCF yield
    3.8%

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    IndegeneINDGN₹15,773 Cr38.534.7913.9%19.0%17.0%0.05+39.6%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 21h ago

    Headlines about Indegene from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    P/E (TTM)
    37.0
    Price / Book
    4.71
    ROE (FY26)
    13.9%
    ROCE (latest year)
    19%
    Dividend yield
    0.34%

    Moving averages (NSE)

    20-day
    ₹616.14
    Price above
    50-day
    ₹601.86
    Price above
    200-day
    ₹530.59
    Price above

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +15.0%
    Profit 3Y CAGR
    +14.7%
    Revenue YoY (Sep 2026)
    +39.6%
    Profit YoY (Sep 2026)
    +9.8%
    Operating margin
    17.0%
    Net margin
    10.0%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    0 Cr500 Cr1K Cr1.5K Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Sep 20260%15%30%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Public
    • DII
    • FII

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-1K Cr-500 Cr0 Cr500 Cr1K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY21FY22FY23FY24FY25FY260%50%100%150%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    -1K Cr0 Cr1K Cr2K Cr3K Cr4K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 20260x2x4x

    Dividends per share

    ₹ by fiscal year of the ex-date; the latest year runs to date.

    FY26FY27₹0₹1₹2₹3

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales6736736766877207567618049421,0031,0631,122
    Expenses524534548561589608606664783840889937
    Operating Profit149139129126132148155141160164174186
    OPM %22%21%19%18%18%20%20%17%17%16%16%17%
    Other Income132622213826222019-102915
    Interest121212433445767
    Depreciation181820192021222340424446
    Profit before tax132134120124146149152133135105153147
    Tax %25%29%27%26%25%21%23%23%24%24%24%24%
    Net Profit9995889211011811610210380116112
    EPS in Rs₹4.44₹4.26₹3.67₹3.83₹4.58₹4.90₹4.85₹4.25₹4.28₹3.31₹4.82₹4.66

    From company filings, updated 19 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days102

    -6 days since Mar 2021

    Cash Conversion Cycle102

    -6 days since Mar 2021

    Working Capital Days5

    -40 days since Mar 2021

    Strengths, risks & growth

    Incorporated in 1998, Indegene Ltd provides solutions consisting of analytics, technology and commercial, medical, regulatory and safety services to life science and health care organizations [1]

    Strengths

    • Company is almost debt free.
    • Company is expected to give good quarter

    Risks

    None flagged by the checklist.

    Compounded Sales Growth

    10 Years
    —
    5 Years
    +29%
    3 Years
    +15%
    TTM
    +36%

    Compounded Profit Growth

    10 Years
    —
    5 Years
    +23%
    3 Years
    +16%
    TTM
    -4%

    Stock Price CAGR

    10 Years
    —
    5 Years
    —
    3 Years
    —
    1 Year
    +27%

    Return on Equity

    10 Years
    —
    5 Years
    +21%
    3 Years
    +19%
    Last Year
    +14%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    FII11.48%10.27%9.92%12.40%+2.48 pp
    DII8.06%8.29%8.74%15.82%+7.08 pp
    Public80.44%81.43%81.34%71.76%-9.58 pp

    Filed with NSE for Sept 2026: promoters 0.00%, public 100.00%

    Analysts & fund holdings

    88%
    88% recommend buy
    8 analysts cover the stock
    Valuation vs Commercial Services & Supplies
    P/E38.5 vs 44.3
    Sector P/B5.80

    Who holds the shares, quarter by quarter

    Mutual funds 12.25% (+6.97 pp)
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    • Promoters0.0%
    • Foreign institutions12.4%
    • Mutual funds12.3%
    • Insurance0.1%
    • Other domestic institutions3.5%
    • Retail7.6%
    • Others64.2%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    Quant Small Cap Fund3.35%1.58%+1.58 pp
    ICICI Pru Small Cap Fund0.73%1.20%+0.68 pp
    ICICI Pru Healthcare Fund0.70%1.56%+1.56 pp
    Sundaram Mid Cap Fund0.58%0.68%+0.13 pp
    ICICI Pru Technology Fund0.57%0.70%-0.01 pp

    Scorecard

    Performance
    Low
    Valuation
    High
    Growth
    Avg
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Risk & trend

    From 292 daily sessions to 18 Nov 2026.

    Computed

    Risk

    Volatility (1Y)
    28.2%
    Downside volatility
    23.9%
    Worst 5% of days
    2.6%
    Average of that tail
    3.3%
    Max drawdown (1Y)
    27.8%
    Below its peak
    1.7%

    Against the market

    Beta vs Nifty 50
    0.70
    Correlation
    0.34
    Relative strength (3M)
    +12.7%
    ATR (14)
    3.3%

    Return

    Return 1M
    +9.5%
    Return 3M
    +16.6%
    Return 6M
    +28.4%
    Return 1Y
    +26.4%
    vs 200-day average
    +23.4%

    Momentum

    RSI (14)
    64.5
    MACD histogram
    4.90
    Stochastic %K
    78.0
    ADX (14)
    24.7
    +DI / −DI
    28.0 / 13.6
    Money flow index
    74.0

    Participation

    Delivery (20d avg)
    61.7%
    vs its 60-day baseline
    +5.6 pts
    Volume vs 20-day
    -0.6σ
    Close vs day's VWAP
    +0.0%
    52-week position
    95 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Sept 2026.

    Computed

    Piotroski F-Score

    1 of 6 tested

    • Return on assets positive — passed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — failed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — failed
    • Current ratio improving — failed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — failed
    • Asset turnover improving — failed
    Free cash flow
    ₹606 Cr
    FCF yield
    3.8%
    Cash conversion
    1.62
    Accruals ratio
    -0.054
    Net debt
    ₹16 Cr
    Net debt / equity
    0.00
    EV / sales
    3.82
    Capex intensity
    1.3%
    Revenue CAGR
    30.1%
    Profit CAGR
    -3.0%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Insider trades

    Last 12 months, market trades
    Net selling ₹1.9 Cr
    1 buys · ₹100.0 L
    1 sells · ₹2.9 Cr
    Latest insider trades disclosed to NSE
    PersonTypeSharesValueDisclosed
    Anita Nair
    Immediate relative · Market Purchase
    Buy22,230₹100.0 L24 Mar 2026
    Sameer Narendrakumar Lal
    Other · Market Sale
    Sell60,000₹2.9 Cr4 Mar 2026
    Sameer Narendra Lal
    Market Sale
    Sell10,000₹51.3 L18 Nov 2025
    BINA PATIL
    Market Sale
    Sell2,000₹10.3 L14 Nov 2025
    BINA PATIL
    Market Sale
    Sell5,930₹31.1 L14 Nov 2025
    BINA PATIL
    Market Sale
    Sell500₹2.6 L14 Nov 2025
    BINA PATIL
    Market Sale
    Sell13,570₹69.8 L14 Nov 2025
    AMIT GUPTA
    Sell2,200₹11.4 L14 Nov 2025
    AMIT GUPTA
    Sell2,200₹11.4 L14 Nov 2025
    AMIT GUPTA
    Sell2,200₹11.4 L14 Nov 2025
    BINA SANJEEV PATIL
    Market Sale
    Sell5,930₹31.1 L13 Nov 2025
    BINA SANJEEV PATIL
    Market Sale
    Sell500₹2.6 L13 Nov 2025

    Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.

    Corporate actions

    • dividend
      ₹2.25

      Dividend - Rs 2.25 Per Share

      31 Jul 2026
      ex-date
    • dividend
      ₹2.00

      Dividend - Rs 2 Per Share

      13 Jun 2025
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      29 Aug 2024
      ex-date

    Company announcements

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation of Investors / Analysts Meeting

    Company Update
    Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    Transcript of the Q2 FY27 Earnings Call

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Intimation of Newspaper Publication

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    Audio Recording of the Q2 FY27 Earnings Call

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Audio Recording of the Q2 FY27 Earnings Call

    Company Update
    Announcement under Regulation 30 (LODR)-Investor Presentation

    Analyst Presentation and Fact Sheet - financial results for the 2nd quarter and half year ended 30th September, 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Press Release

    Company Update
    Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer

    Intimation of Resignation of Ms. Srishti Ramesh Kaushik (M. No A21609) from the position of Company Secretary, Compliance Officer and Key Managerial Personnel of the Company.

    Company Update
    Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    Allotment of shares under RSU Scheme 2020 and ESOP Scheme 2020

    Result
    Unaudited Financial Results For The 2Nd Quarter And Half Year Ended 30Th September, 2026

    Unaudited Financial Results for the 2nd quarter and half year ended 30th September 2026

    Board Meeting
    Board Meeting Outcome for The Meeting Of The Board Of Directors Held On 29 October, 2026

    Outcome of the Board Meeting

    Company UpdatePrice-sensitive
    Announcement under Regulation 30 (LODR)-Acquisition

    Acquisition

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Press Release

    Company Update
    Announcement under Regulation 30 (LODR)-Resignation of Director

    Resignation of Mr. Mark Francis Dzialga (DIN: 00955485) from the position of Non-Executive Non Independent Director of the Company

    Company Update
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Certificate under Regulation 74 (5) of SEBI DP Regulations, 2018

    Filed with BSE (scrip 544172); the last 45 days. Documents open at bseindia.com.

    Documents

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 30 Oct 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Indegene: common questions

    Answered from the figures on this page.

    Indegene last traded at ₹654.95 (NSE, as of 18 Nov 2026). The last session moved it up 0.96%.

    Indegene is valued at about ₹15,773 crore (NSE, as of 18 Nov 2026).

    Indegene trades at a price-to-earnings ratio of 38.53 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Indegene has traded between ₹414.00 and ₹677.00 over the past 52 weeks, to 18 Nov 2026. It is currently 92% of the way up that range.

    Indegene (INDGN) is classified under Pharma on this site's screener.